Paul Glue (P Glue)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 23

Top Topics

Systematic Review

Major Depressive Disorder

Top Venues

Journal of psychopharmacology (Oxford, England)

Nature medicine

Therapeutic advances in psychopharmacology

Psychological medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Paul Glue, Shona Neehoff, Ben Beaglehole, Shabah Shadli, Neil McNaughton, Natalie J Hughes-Medlicott
Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. Journal of psychopharmacology (Oxford, England) 38 (2) (2024)
Paul Glue, Colleen Loo, Johnson Fam, Hsien-Yuan Lane, Allan H Young, Peter Surman, null null
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nature medicine 30 (7) (2024)
Paul Glue, Colleen Loo, Johnson Fam, Hsien-Yuan Lane, Allan H Young, Peter Surman, null null
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nature medicine 30 (7) (2024)
Paul Glue, Shona Neehoff, Ben Beaglehole, Shabah Shadli, Neil McNaughton, Natalie J Hughes-Medlicott
Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. Journal of psychopharmacology (Oxford, England) (2024)
Paul Glue, Colleen Loo, Johnson Fam, Hsien-Yuan Lane, Allan H Young, Peter Surman, null null
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nature medicine 30 (7) (2024)
Paul Glue, Shona Neehoff, Ben Beaglehole, Shabah Shadli, Neil McNaughton, Natalie J Hughes-Medlicott
Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. Journal of psychopharmacology (Oxford, England) 38 (2) (2024)
Paul Glue, Colleen Loo, Johnson Fam, Hsien-Yuan Lane, Allan H Young, Peter Surman, null null
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nature medicine 30 (7) (2024)
Paul Glue, Colleen Loo, Johnson Fam, Hsien-Yuan Lane, Allan H Young, Peter Surman, null null
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nature medicine (2024)
Paul Glue, Shona Neehoff, Ben Beaglehole, Shabah Shadli, Neil McNaughton, Natalie J Hughes-Medlicott
Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. Journal of psychopharmacology (Oxford, England) 38 (2) (2024)
Paul Glue, Shona Neehoff, Ben Beaglehole, Shabah Shadli, Neil McNaughton, Natalie J Hughes-Medlicott
Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. Journal of psychopharmacology (Oxford, England) 38 (2) (2024)
Shabah M Shadli, Carina J Donegan, Muhammad Ss Bin Mohd Fahmi, Bruce R Russell, Paul Glue, Neil McNaughton
Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression? Journal of psychopharmacology (Oxford, England) (2024)
Paul Glue, Shona Neehoff, Ben Beaglehole, Shabah Shadli, Neil McNaughton, Natalie J Hughes-Medlicott
Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. Journal of psychopharmacology (Oxford, England) 38 (2) (2024)
Ben Stegmann, Chris Gale, Paul Glue
Maintenance ECT treatment in New Zealand: Local and national data. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists (2022)
Jessie Lenagh-Glue, John Dawson, Johnnie Potiki, Anthony J O'Brien, Katey Thom, Heather Casey, Paul Glue
Use of advance directives to promote supported decision-making in mental health care: Implications of international trends for reform in New Zealand. The Australian and New Zealand journal of psychiatry (2022)
Elizabeth Whittaker, Alisher R Dadabayev, Sonalee A Joshi, Paul Glue
Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic advances in psychopharmacology 11 (2021)
Aindrea Brown, Paul Glue
Possible mechanisms for treatment heterogeneity in clinical trials of adjunctive N-acetylcysteine for bipolar depression. Bipolar disorders (2021)
Shabah M Shadli, Lynne C Ando, Julia McIntosh, Veema Lodhia, Bruce R Russell, Ian J Kirk, Paul Glue, Neil McNaughton
Right frontal anxiolytic-sensitive EEG 'theta' rhythm in the stop-signal task is a theory-based anxiety disorder biomarker. Scientific reports 11 (1) (2021)
Neil McNaughton, Paul Glue
Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders. Personality neuroscience 3 (2020)
Dylan Truppman Lattie, Hayley Nehoff, Shona Neehoff, Andrew Gray, Paul Glue
Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. Journal of psychopharmacology (Oxford, England) 35 (2) (2020)
Paul Glue, Natalie J Medlicott, Shona Neehoff, Peter Surman, Fred Lam, Noelyn Hung, Cheung-Tak Hung
Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. Therapeutic advances in psychopharmacology 10 (2020)
Paul Glue, Bruce Russell, Natalie J Medlicott
Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review. European journal of clinical pharmacology 77 (5) (2020)
Paul Glue, Shona Neehoff, Amandine Sabadel, Lucy Broughton, Martin Le Nedelec, Shabah Shadli, Neil McNaughton, Natalie J Medlicott
Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of psychopharmacology (Oxford, England) 34 (3) (2019)
Christopher Gale, Paul Glue, Yoram Barak
Low-risk and high-risk groups matter in suicide risk. Psychological medicine 49 (5) (2018)